GHSR-1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Psychedelic culture includes manifestations such as psychedelic music, psychedelic art, psychedelic literature, psychedelic film, and psychedelic festivals. Examples of psychedelic music are found in the work of 1960s rock bands like the Grateful Dead, Jefferson Airplane, The 13th Floor Elevators, and Syd Barrett-era Pink Floyd. Many psychedelic bands and elements of the psychedelic subculture originated in San Francisco during the mid to late 1960s.
The mechanism describing the formation of the ozone layer was described by British mathematician and geophysicist Sydney Chapman in 1930, and is known as the Chapman cycle or ozone–oxygen cycle. Molecular oxygen absorbs high energy sunlight in the UV-C region, at wavelengths shorter than about 240 nm. Radicals produced from the homolytically split oxygen molecules combine with molecular oxygen to form ozone. Ozone in turn is photolyzed much more rapidly than molecular oxygen as it has a stronger absorption that occurs at longer wavelengths, where the solar emission is more intense. Ozone (O3) photolysis produces O and O2. The oxygen atom product combines with atmospheric molecular oxygen to reform O3, releasing heat. The rapid photolysis and reformation of ozone heat the stratosphere, resulting in a temperature inversion. This increase of temperature with altitude is characteristic of the stratosphere; its resistance to vertical mixing means that it is stratified. Within the stratosphere temperatures increase with altitude (see temperature inversion); the top of the stratosphere has a temperature of about 270 K (−3°C or 26.6°F). This vertical stratification, with warmer layers above and cooler layers below, makes the stratosphere dynamically stable: there is no regular convection and associated turbulence in this part of the atmosphere. However, exceptionally energetic convection processes, such as volcanic eruption columns and overshooting tops in severe supercell thunderstorms, may carry convection into the stratosphere on a very local and temporary basis.
=== Medications === Certain medications increase the risk of hyperglycemia, including: corticosteroids, octreotide, beta blockers, epinephrine, thiazide diuretics, niacin, pentamidine, protease inhibitors, L-asparaginase, statins and antipsychotics. The administration of amphetamines initially produces hyperglycemia but later produces hypoglycemia. Thiazides are used to treat hypertension in type 2 diabetes but also may cause hyperglycemia.
=== Ryan Crowley === Ryan Crowley was drafted to the Fremantle Football Club in 2002 and played his first AFL game in 2005. He tested positive to a banned substance on match day in the season of 2014. The banned substance was in a painkiller, known as methadone, that he had taken two pills of prior to the game due to back pain. This was not prescribed by the club doctor. He was given a 12-month ban from playing in the AFL but still trained with his team. He became able to play on 25 September 2015, and after being delisted by Fremantle at season's end, joined Essendon as a top-up player due to the club's supplements saga.
=== Optimization of protein crystallization conditions === Although proteins are dynamic structures in solution, formation of protein crystals is expected to be favored when all molecules lie in their lowest energy conformation. Thermofluor evaluation of conditions that stabilize proteins is consequently a useful strategy for finding optimal crystallization conditions
Sources: en.wikipedia.org
Dendral was a project in artificial intelligence (AI) of the 1960s, and the computer software expert system that it produced. Its primary aim was to study hypothesis formation and discovery in science. For that, a specific task in science was chosen: help organic chemists in identifying unknown organic molecules, by analyzing their mass spectra and using knowledge of chemistry. It was done at Stanford University by Edward Feigenbaum, Bruce G. Buchanan, Joshua Lederberg, and Carl Djerassi, along with a team of highly creative research associates and students. It began in 1964 and spans approximately half the history of AI research. The software program Dendral is considered the first expert system because it automated the decision-making process and problem-solving behavior of organic chemists. The project consisted of research on two main programs Heuristic Dendral and Meta-Dendral, and several sub-programs. It was written in the Lisp programming language, which was considered the language of AI because of its flexibility. Many systems were derived from Dendral, including MYCIN, MOLGEN, PROSPECTOR, XCON, and STEAMER. There are many other programs today for solving the mass spectrometry inverse problem, see List of mass spectrometry software, but they are no longer described as 'artificial intelligence', just as structure searchers. The name Dendral is an acronym of the term "Dendritic Algorithm".
=== Exposure-response === Exposure-Response models establish the relationship between drug exposure and clinical response. They play a crucial role in determining the optimal therapeutic range and predicting the likelihood of efficacy or adverse events. These models not only guide dose individualization based on desired clinical outcomes but also provide information on population exposure-response relationships for effects and adverse effects.
Department of Health and Human Services estimating in 2008 that fifty-seven million adults aged twenty and older were pre-diabetic, 23.6 million diabetic, with 90–95% of the latter being type 2-diabetic. Obesity has also been shown to increase the prevalence of complications during pregnancy and childbirth. Babies born to obese women are almost three times as likely to die within one month of birth and almost twice as likely to be stillborn than babies born to women of normal weight.
=== Biomaterials === Fluorescent biomaterials are a possible way of using external factors to observe a pathway more visibly. The method involves fluorescently labeling peptide molecules that would alter an organism's natural pathway. When this peptide is inserted into the organism's cell, it can induce a different reaction. This method can be used, for example to treat a patient and then visibly see the treatment's outcome.
Sources: en.wikipedia.org
=== Prevention of suicide === Lithium has been shown to reduce the risk of suicide in individuals with bipolar disorder or major depression to close to the same level as that of the general population. It is thought to exert this effect by treating the underlying mood disorder and through a reduction in impulsivity and aggressiveness. Lithium is proven to reduce the risk of suicide in mood disorders by 87% in randomized double-blind placebo-controlled trials. Some meta-analyses have not found a statistically significant association between lithium and a reduction in suicide, however these meta-analyses are disputed. Some evidence suggests lithium is effective in significantly reducing the risk of self-harm and unintentional injury for bipolar disorder in comparison to no treatment and to antipsychotics or valproate. In addition, lithium decreases all-cause mortality in people with bipolar disorder. The increased presence of trace amounts of lithium in drinking water is correlated with lower overall suicide rates, especially among men. Lithium in drinking water is also associated with lower rates of homicide, rape, drug arrests, and other crimes.
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate. Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France. This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. As of January 2014, it was in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016. As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers. In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.
isochromosome A type of abnormal chromosome in which the arms of the chromosome are mirror images of each other. Isochromosome formation is equivalent to simultaneous duplication and deletion events such that two copies of either the long arm or the short arm comprise the resulting chromosome.
Philip wrote a contract giving Tessa half of all the rights to the novel, which stated that Tessa "participated to a great extent in writing the outline and novel A Scanner Darkly with me, and I owe her one half of all income derived from it". There was also the challenge of transmuting the events into "science fiction", as Dick felt that he could not sell a mainstream or literary novel after several previous failures. Providing invaluable aid in this field was Judy-Lynn del Rey, head of Ballantine Books' SF division, which had optioned the book. Del Rey suggested the timeline change to 1994 and emphasized the more futuristic elements of the novel, such as the "scramble suit" employed by Fred (which, incidentally, emerged from one of the mystical experiences). Yet much of the dialogue spoken by the characters used hippie slang, dating the events of the novel to their "true" time-frame of 1970–72. Upon its publication in 1977, A Scanner Darkly was hailed by ALA Booklist as "his best yet!" Brian Aldiss lauded it as "the best book of the year", while Robert Silverberg praised the novel as "a masterpiece of sorts, full of demonic intensity", but concluded that "it happens also not to be a very successful novel... a failure, but a stunning failure". Spider Robinson panned the novel as "sometimes fascinating, sometimes hilarious, [but] usually deadly boring". Sales were typical for the SF genre in America, but hardcover editions were issued in Europe, where all of Dick's works were warmly received.
Scarification involves scratching, etching, burning/branding, or superficially cutting designs, pictures, or words into the skin as a permanent body modification or body art. The body modification can take roughly 6–12 months to heal. In the process of body scarification, scars are purposely formed by cutting or branding the skin by various methods (sometimes using further sequential aggravating wound-healing methods at timed intervals, like irritation). Scarification is sometimes called cicatrization.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.